Sarepta hit by new short attack; general biotech selloff

|About: Sarepta Therapeutics, Inc. (SRPT)|By:, SA News Editor

Clinical trial data for eteplirsen not enough for early/accelerated FDA approval is among the claims of research shop Favus in what Adam Feuerstein calls a "rehash of old short arguments."

Sarepta Therapeutics (SRPT -8.4%).

Not helping is a second straight day of big declines for momentum names in general and biotech stocks in particular.